Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Diabetes, Obesity and Metabolism · 2023-04 · 25 (4) · 975-984
DOI: 10.1111/dom.14944 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.01.2023. Verfasst von Mojca Jensterle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Gastric Emptying, Polycystic Ovary Syndrome. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Javna Agencija za Raziskovalno Dejavnost RS.
Abstract (Originalsprache)
Aim
To evaluate the effect of once‐weekly subcutaneous semaglutide 1.0 mg on the late digestive period of gastric emptying (GE) after ingestion of a standardized solid test meal by using technetium scintigraphy, the reference method for this purpose.
Methods
We conducted a single‐blind, placebo‐controlled trial in 20 obese women with polycystic ovary syndrome (PCOS; mean [range] age 35 [32.3‐40.8] years, body mass index 37 [30.7‐39.8] kg/m 2 ) randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 12 weeks. GE was assessed after ingestion of [ 99mT c] colloid in a pancake labelled with radiopharmaceutical by scintigraphy using sequential static imaging and dynamic acquisition at baseline and at Week 13. Estimation of GE was obtained by repeated imaging of remaining [ 99mT c] activity at fixed time intervals over the course of 4 hours after ingestion.
Results
From baseline to the study end, semaglutide increased the estimated retention of gastric contents by 3.5% at 1 hour, 25.5% at 2 hours, 38.0% at 3 hours and 30.0% at 4 hours after ingestion of the radioactively labelled solid meal. Four hours after ingestion, semaglutide retained 37% of solid meal in the stomach compared to no gastric retention in the placebo group ( P = 0.002). Time taken for half the radiolabelled meal to empty from the stomach was significantly longer in the semaglutide group than the placebo group (171 vs. 118 min; P < 0.001).
Conclusion
Semaglutide markedly delayed 4‐hour GE in women with PCOS and obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Internal Medicine, Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
- Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
ORCID-Profile: Mojca Jensterle, Andrej Janez
Förderung
- Javna Agencija za Raziskovalno Dejavnost RS
Zitieren
APA
Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023). Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism, 25(4), 975-984. https://doi.org/10.1111/dom.14944
Vancouver
Jensterle M, Ferjan S, Ležaič L, Sočan A, Goričar K, Zaletel K, et al. Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. 2023;25(4):975-984. doi:10.1111/dom.14944
BibTeX
@article{Jensterle2023,
author = {Jensterle, Mojca and Ferjan, Simona and Ležaič, Luka and Sočan, Aljaž and Goričar, Katja and Zaletel, Katja and Janez, Andrej},
title = {Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {4},
pages = {975--984},
doi = {10.1111/dom.14944}
}
EUVIMED